ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "safety and tofacitnib"

  • Abstract Number: 439 • 2013 ACR/ARHP Annual Meeting

    Tofacitinib, An Oral Janus Kinase Inhibitor: Analysis Of Gastrointestinal Adverse Events Across The Rheumatoid Arthritis Clinical Program

    E. B. Lee1, J. R. Curtis2, R. Riese3, C. A. Connell3, R. Chew3, M.G. Boy3, E. Maller4, C. Su4 and L. Wang3, 1Seoul National University, Seoul, South Korea, 2Rheumatology & Immunology, University of Alabama at Birmingham, Birmingham, AL, 3Pfizer Inc, Groton, CT, 4Pfizer Inc, Collegeville, PA

    Background/Purpose: Tofacitinib is a novel, oral Janus kinase inhibitor being investigated as a targeted immunomodulator in rheumatoid arthritis (RA). This analysis aimed to describe and…
  • Abstract Number: 2331 • 2013 ACR/ARHP Annual Meeting

    Efficacy and Safety Of Tofacitinib In Older and Younger Patients With Rheumatoid Arthritis

    J. R. Curtis1, H. Schulze-Koops2, L Takiya3, C. A. Mebus4, K. Terry4, R. Chew4 and T. V. Jones3, 1Rheumatology & Immunology, University of Alabama at Birmingham, Birmingham, AL, 2University of Munich, Munich, Germany, 3Pfizer Inc, Collegeville, PA, 4Pfizer Inc, Groton, CT

    Background/Purpose: Tofacitinib is a novel, oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). The clinical development program for tofacitinib in RA enrolled ˃500…
  • Abstract Number: 2328 • 2013 ACR/ARHP Annual Meeting

    Tofacitinib, An Oral Janus Kinase Inhibitor, In The Treatment Of Rheumatoid Arthritis: Open-Label, Long-Term Extension Safety and Efficacy Up To 5 Years

    Jürgen Wollenhaupt1, Joel Silverfield2, Eun Bong Lee3, Susan P. Wood4, Ketti K. Terry4, Hiroyuki Nakamura5, Yukako Ohno5, David Gruben4, Birgitta Benda6, Lisy Wang4 and Richard Riese4, 1Schoen-Klinik Hamburg-Eilbek Teaching Hospital of the University of Hamburg, Hamburg, Germany, 2Healthpoint Medical Group, Tampa, FL, 3Seoul National University, Seoul, South Korea, 4Pfizer Inc, Groton, CT, 5Pfizer Japan Inc, Tokyo, Japan, 6Pfizer Inc, Collegeville, PA

    Background/Purpose: Tofacitinib is a novel, oral JAK inhibitor for the treatment of rheumatoid arthritis (RA). Here we report tofacitinib safety, tolerability, and durability of response…
  • Abstract Number: 1471 • 2013 ACR/ARHP Annual Meeting

    Tofacitinib For Rheumatoid Arthritis: A Systematic Review and Meta-Analysis

    Maria A. Lopez-Olivo1, Maria E. Suarez-Almazor2 and Mahesh Bavineni3, 1General Internal Medicine, University of Texas. M.D Anderson Cancer Center, Houston, TX, 2The Department of General Internal Medicine, The University of Texas, MD Anderson Cancer Center, Houston, TX, 3Internal Medicine, Louisiana State University Lafayette, Lafayette, LA

    Background/Purpose: Tofacitinib was developed as a small molecule inhibitor of the Janus kinase (JAK) pathways that are central to the maintenance of the inflammatory state…
  • Abstract Number: 802 • 2013 ACR/ARHP Annual Meeting

    Tofacitinib, An Oral Janus Kinase Inhibitor: Analysis Of Malignancies Across The Rheumatoid Arthritis Clinical Program

    X. Mariette1, J. R. Curtis2, E. B. Lee3, B. Benda4, I. Kaplan5, K. Soma5, R. Chew5, J. Geier6, L. Wang7 and R. Riese5, 1Paris-Sud University, Paris, France, 2Rheumatology & Immunology, University of Alabama at Birmingham, Birmingham, AL, 3Seoul National University, Seoul, South Korea, 4Pfizer Inc, Collegeville, PA, 5Pfizer Inc, Groton, CT, 6Pfizer Inc, New York, NY, 7Pfizer Worldwide R&D, Cambridge, MA

    Background/Purpose: Tofacitinib is a novel, oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). This analysis extended the evaluation of malignancies that occurred…
  • Abstract Number: 441 • 2013 ACR/ARHP Annual Meeting

    Tofacitinib, An Oral Janus Kinase Inhibitor: Safety Comparison In Patients With Rheumatoid Arthritis and An Inadequate Response To Nonbiologic Or Biologic Disease‑Modifying Anti-Rheumatic Drugs

    G. R. Burmester1, C Charles-Schoeman2, J. D. Isaacs3, T. Hendrikx4, K. Kwok5, S. H. Zwillich6 and R. Riese6, 1Department of Medicine/Rheumatology and Clinical Immunology and German Rheumatism Research Centre Berlin (DRFZ), Charité University Medicine Berlin, Berlin, Germany, 2University of California, Los Angeles, CA, 3Newcastle University, Newcastle-upon-Tyne, United Kingdom, 4Pfizer BV, Capelle aan den IJssel, Netherlands, 5Pfizer Inc, New York, NY, 6Pfizer Inc, Groton, CT

    Background/Purpose: Tofacitinib is a novel, oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). This analysis provides comparative safety data on the incidence…
  • Abstract Number: 442 • 2013 ACR/ARHP Annual Meeting

    Tolerability and Non-Serious Adverse Events In Rheumatoid Arthritis Patients Treated With Tofacitinib As Monotherapy Or In Combination Therapy

    A. Dikranian1, K. Soma2, R. Riese2, D. Gruben2 and T. V. Jones3, 1San Diego Arthritis Medical Clinic, San Diego, CA, 2Pfizer Inc, Groton, CT, 3Pfizer Inc, Collegeville, PA

    Background/Purpose: Tofacitinib is a novel, oral Janus kinase (JAK) inhibitor for the treatment of rheumatoid arthritis (RA). Tolerability remains an ill-defined construct in clinical trials.…
  • Abstract Number: 443 • 2013 ACR/ARHP Annual Meeting

    Efficacy and Safety Analyses Of Tofacitinib From Pooled Phase 2, Phase 3 and Long-Term Extension Rheumatoid Arthritis Studies: US Compared With Non-US Populations

    S. B. Cohen1, Roy Fleischmann1, J. M. Kremer2, A. Koenig3, K. Kwok4, L. Wang5, C. a. Mebus5, R. Riese5 and T. Robinson3, 1Metroplex Clinical Research Center, Dallas, TX, 2Albany Medical College and The Center for Rheumatology, Albany, NY, 3Pfizer Inc, Collegeville, PA, 4Pfizer Inc, New York, NY, 5Pfizer Inc, Groton, CT

    Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor approved in the US for the treatment of rheumatoid arthritis at 5 mg BID. Phase (P) 3…
  • Abstract Number: 438 • 2013 ACR/ARHP Annual Meeting

    Tofacitinib, An Oral Janus Kinase Inhibitor, In A Rheumatoid Arthritis Open-Label Extension Study Following Adalimumab Therapy In A Phase 3 Randomised Clinical Trial

    M. C. Genovese1, R. F. van Vollenhoven2, B. Wilkinson3, L. Wang3, S. H. Zwillich3, D. Gruben3, B. Benda4 and T. V. Jones4, 1Division of Rheumatology, Stanford University, Palo Alto, CA, 2Clinical Trials Unit Department of Rheumatology, The Karolinska Institute, Stockholm, Sweden, 3Pfizer Inc, Groton, CT, 4Pfizer Inc, Collegeville, PA

    Background/Purpose: Tofacitinib is a novel, oral Janus kinase inhibitor for the treatment of rheumatoid arthritis. Here, we describe the efficacy and safety for adalimumab (ADA)…
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology